MedTrace Logo

A Clinical Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate in Vascular Cognitive Impairment Patients

NCT05050604 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 418

Last updated 2021-09-20

No results posted yet for this study

Summary

This is a multi-center, randomized, double-blind, placebo-controlled, Phase IV Trial to evaluate the efficacy and safety of Choline Alfoscerate compared to placebo in Mild Cognitive Impairment Patients with Cerebrovascular Disease

Conditions

  • Vascular Cognitive Impairment

Interventions

DRUG

Choline Alfoscerate 400mg

Choline Alfoscerate 400mg per oral 3 times a day during the entrie treatment period

DRUG

Placebo of Choline Alfoscerate 400mg

Placebo of Choline Alfoscerate 400mg per oral 3 times a day during the entrie treatment period

Sponsors & Collaborators

  • Choline Alfoscerate Re-evaluation Consortium (57 pharmaceutical companies)

    collaborator UNKNOWN

  • Chong Kun Dang Pharmaceutical

    lead INDUSTRY

Principal Investigators

  • Sun U Kwon, MD, PhD · Asan Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-30
Primary Completion
2024-11-30
Completion
2024-11-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05050604 on ClinicalTrials.gov